Dear Sir or Madam,
Immunochina Pharmaceuticals is conducting a ‘Clinical Study of CAR-T Cells for the Treatment of Relapsed and Refractory Acute B Lymphocytic Leukemia’. As a new generation of individualized precise medical technology, CAR-T cellular therapy can modify the immune system through genetic engineering to specifically recognize and kill cancer cells and it has been clinically proven in the world. The study is open to recruiting subjects, and if you are eligible and willing to participate, we will provide you with free treatment and related examinations.
If you, your families or friends have relapsed and refractory acute B lymphocytic leukemia and are not over 75 years old, feel free to contact us and we will evaluate your condition in detail to determine if you are eligible to participate.
If you need further information, please contact Mr. Wu via:
With the greatest efforts and best service, Immunochina is committed to helping every patient to fight against leukemia. We sincerely hope that all patients will get well soon!